Literature DB >> 18349522

Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia.

Alena Banasová1, Hana Maxová, Václav Hampl, Martin Vízek, Viera Povýsilová, Jana Novotná, Olga Vajnerová, Olga Hnilicková, Jan Herget.   

Abstract

BACKGROUND: Chronic hypoxia induces lung vascular remodeling, which results in pulmonary hypertension. Vascular remodeling is associated with collagenolysis and activation of matrix metalloproteinases (MMPs). One of the possible sources of MMPs in hypoxic lung are mast cells.
OBJECTIVE: The role of lung mast cell collagenolytic activity in hypoxic pulmonary hypertension was tested by the inhibitor of mast cell degranulation disodium cromoglycate (DSCG).
METHODS: Rats were treated with DSCG in an early or later phase of isobaric hypoxia. Control groups were exposed to hypoxia only or to normoxia. Lung hemodynamics, muscularization and collagen metabolism in the walls of peripheral pulmonary vessels in the lungs were measured.
RESULTS: DSCG applied at an early phase of exposure to hypoxia reduced the development of pulmonary hypertension, inhibited muscularization in peripheral pulmonary arteries and decreased the amount of collagen cleavage fragments in prealveolar vessels.
CONCLUSIONS: Mast cell degranulation plays a role in the initiation of hypoxic pulmonary vascular remodeling. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349522     DOI: 10.1159/000121410

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  18 in total

1.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Imatinib in pulmonary arterial hypertension: c-Kit inhibition.

Authors:  Samar Farha; Raed Dweik; Franck Rahaghi; Raymond Benza; Paul Hassoun; Robert Frantz; Fernando Torres; Deborah A Quinn; Suzy Comhair; Serpil Erzurum; Kewal Asosingh
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

Review 3.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

4.  Are mast cells implicated in asphyxia?

Authors:  Barbara Muciaccia; Cristina Sestili; Stefania De Grossi; Annarita Vestri; Luigi Cipolloni; Rossana Cecchi
Journal:  Int J Legal Med       Date:  2015-06-11       Impact factor: 2.686

Review 5.  Lung Circulation.

Authors:  Karthik Suresh; Larissa A Shimoda
Journal:  Compr Physiol       Date:  2016-03-15       Impact factor: 9.090

Review 6.  Mast cells: an expanding pathophysiological role from allergy to other disorders.

Authors:  Preet Anand; Baldev Singh; Amteshwar Singh Jaggi; Nirmal Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-06       Impact factor: 3.000

Review 7.  The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.

Authors:  Steven C Pugliese; Jens M Poth; Mehdi A Fini; Andrea Olschewski; Karim C El Kasmi; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-21       Impact factor: 5.464

8.  New dynamic viewing of mast cells in pulmonary arterial hypertension (PAH): contributors or outsiders to cardiovascular remodeling.

Authors:  Jian Xu; Jingjing Wang; Chengjie Shao; Xiaoning Zeng; Lixiang Sun; Hui Kong; Weiping Xie; Hong Wang
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

9.  Mast cell number, phenotype, and function in human pulmonary arterial hypertension.

Authors:  Samar Farha; Jacqueline Sharp; Kewal Asosingh; Margaret Park; Suzy A A Comhair; W H Wilson Tang; Jim Thomas; Carol Farver; Fred Hsieh; James E Loyd; Serpil C Erzurum
Journal:  Pulm Circ       Date:  2012 Apr-Jun       Impact factor: 3.017

10.  Chronic obstructive pulmonary disease phenotype desaturator with hypoxic vascular remodelling and pulmonary hypertension obtained by cluster analysis.

Authors:  Domenico Maurizio Toraldo; Mauro Minelli; Francesco De Nuccio; Giuseppe Nicolardi
Journal:  Multidiscip Respir Med       Date:  2012-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.